CORE--CLINICAL RESEARCH DEVELOPMENT

阿尔茨海默病（AD）的持续科学进展依赖于 研究患者和对照的可用性， 痴呆症的临床诊断，以及交流和合作 不同学科的研究人员之间， 疾病 临床研发核心的主要目标是 促进遗传家族研究和其他多学科 布赖恩ADRC的努力，提供所需的基本病人材料， 这些调查。 临床有四个具体目标 内核： 1)对有记忆障碍的患者进行诊断评估。 我们 计划专注于持续的高质量患者评估。 我们也将 继续探索将我们的服务扩展到”非洲裔美国人“的方法， 在该中心任职人数不足的老年人。 2)从患者基础、先证者和家庭中确定适合于 阿尔茨海默病的遗传家族研究。 有50多个家庭 入组有多代AD证据的中心 尸检确认。 我们计划继续开发更多 信息丰富的家庭，并评估这些参与者，无论是在 记忆障碍诊所或为方便患者，在家里。 3)促进阿尔茨海默病的临床研究。 的 临床核心将继续成为研究的资源， Bryan ADRC和研究资源批准的外部研究， 审查委员会。 我们还旨在探索如何提高临床 诊断（例如计算机化评估、诊断算法）， 优化提供给合作者的数据质量。 4)进行阿尔茨海默病的治疗药物干预试验。 随着AD生物学的进步，我们期待着全新类型的 在不久的将来，这些化合物可用于测试。 我们有一个 用于招募患者参与研究的完善基础设施。 通过核心B的研究和资源审查委员会，我们计划 继续为记忆障碍患者筛选有前景的药物方案， 紊乱

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of patients and controls for study, the reliability of the clinical diagnoses of dementia, and the interchange and collaboration between investigators across disciplines working on different aspects of the illness. The main goal of the Clinical Research Development Core is to facilitate the genetic family studies and the other multidisciplinary efforts of the Bryan ADRC by providing the basic patient material needed for these investigations. There are four specific aims of the Clinical Core: 1) Provide diagnostic assessment of patients with memory complaints. We plan to focus on continued high quality patient evaluation. We also will continue to explore ways to extend our services" to African American elderly who have been under-represented in the Center. 2) Identify from the patient base, probands and families appropriate for genetic family studies of Alzheimer's disease. There are over 50 families enrolled in the center in which there is multigenerational evidence of AD with autopsy confirmation. We plan to continue to develop additional informative families and to evaluate these participants either in the Memory Disorders Clinic or, for patients convenience, in the home. 3) Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC and to external studies approved by the Research Resource and Review Committee. We also aim to explore ways to enhance clinical diagnosis (e.g. computerized assessment, diagnostic algorithms) thereby optimizing the quality of the data provided to collaborators. 4) Conduct therapeutic drug intervention trials for Alzheimer's disease. With the advances in the biology of AD, we expect that whole new classes of compounds may become available for testing in the near future. We have a well developed infrastructure for recruiting patients into studies. Through the Research and Resource Review Committee of Core B we plan to continue to screen for promising drug protocols for patients with memory disorders.